Drugs / MK-4166
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03707457 | Mar → Nov 2019 | glioblastoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded |
| Phase 1 | NCT02132754 | Jun 2014 → Jul 2019 | cancer | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-4166 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03707457 ↗ |
| Action | Activate | “humanized IgG1 agonist mAb targeting glucocorticoid-induced TNF receptor (GITR)” PMID 33355238 ↗ Dec 2020 |
| Modality | Monoclonal antibody | “humanized IgG1 agonist mAb” PMID 33355238 ↗ Dec 2020 |
| Route | Intravenous | “MK-4166 IV” NCT02132754 ↗ |